Philips has become the latest company to reveal the impact that tariffs will have on its business, forecasting a €250m–€300m ($284m–$340m) headwind in 2025 despite “substantial mitigations”. The Dutch medtech giant remained firm on its sales growth for the year ahead, predicting an increase of 1–3% as per its first quarter (Q1) earnings report. However, Philips’ full-year margin range was not left untouched, with the company cutting it by one percentage point, down to 10.8–11.3% from 11.8–12.3%. The 2025 outlook was set against Q1 revenue that was down 2% from the same period in 2024, totalling €4.1bn. Philips’ calculation is based on the current tariffs between the US and China and between the US and the rest of the world. The company also based its forecast on the expected resumption of existing international tariffs later this year. US President Donald Trump’s ongoing trade war has brought instability to many industries, with healthcare being no exception. His sweeping tariffs have disrupted medical device supply chains globally. Levies placed on China have particularly impaired procurement channels with components of devices made in the Asian country. Retaliatory tariffs and increased anti-corruption drives imposed by the Chinese Government have also significantly affected market dynamics. In an earnings call, Philips chief financial officer Charlotte Hanneman commented that the US-China tariffs account for most of the headwinds expected by the company. Philips stated that it continues to anticipate 2025 performance will be skewed towards the latter part of the year, with Q2 showing modest improvement. However, Hanneman admitted that tariffs will have a more pronounced effect in the second half of the year. “In an uncertain macro environment that has intensified due to the potential impact of tariffs, we are driving profitable growth, and we are focusing on what we can control,” CEO Roy Jakobs said on the earnings call. Shared pain in Trump’s trade battlefield Shares in nearly all the major medical device players have already taken a hit this year as companies grapple with the fallout from Trump’s trade war. Zimmer Biomet lowered its 2025 earnings forecast in its Q1 earnings report, predicting a $60m-80m headwind due to the tariffs. GE HealthCare, for whom China is a key market for diagnostic imaging products, expects a greater impact, bracing itself for a financial setback of around $500m. Robotic surgical system developer Intuitive, despite a strong Q1 on the back of a widening launch of its latest da Vinci product, lowered its full-year profit margin because of tariffs. Story Continues GlobalData senior medical analyst Ashley Clarke said: “The procurement planning for 2025 and beyond could face more scrutiny if pricing or access to key components becomes less certain. "If trade disruptions extend into next year, both manufacturers and buyers will need to adapt. Vendors with high offshore exposure, particularly those relying on China, India, or EU-based services, may face pressure to localise or diversify production supply chains.” Navigate the shifting tariff landscape with real-time data and market-leading analysis. Request a free demo from GlobalData’s Strategic Intelligence here. "Philips braces for potential $340m hit from Trump’s tariffs" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. View Comments
Philips braces for potential $340m hit from Trump’s tariffs
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...